Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 301

Similar articles for PubMed (Select 14770192)

1.

Health-related quality of life in a randomised placebo-controlled trial of sibutramine in obese patients with type II diabetes.

Kaukua JK, Pekkarinen TA, Rissanen AM.

Int J Obes Relat Metab Disord. 2004 Apr;28(4):600-5.

PMID:
14770192
2.

Weight loss with sibutramine improves glycaemic control and other metabolic parameters in obese patients with type 2 diabetes mellitus.

Fujioka K, Seaton TB, Rowe E, Jelinek CA, Raskin P, Lebovitz HE, Weinstein SP; Sibutramine/Diabetes Clinical Study Group.

Diabetes Obes Metab. 2000 Jun;2(3):175-87.

PMID:
11220553
3.

Use of sibutramine in overweight adult hispanic patients with type 2 diabetes mellitus: a 12-month, randomized, double-blind, placebo-controlled clinical trial.

Sánchez-Reyes L, Fanghänel G, Yamamoto J, Martínez-Rivas L, Campos-Franco E, Berber A.

Clin Ther. 2004 Sep;26(9):1427-35.

PMID:
15531005
4.
5.

Use of sibutramine in obese mexican adolescents: a 6-month, randomized, double-blind, placebo-controlled, parallel-group trial.

García-Morales LM, Berber A, Macias-Lara CC, Lucio-Ortiz C, Del-Rio-Navarro BE, Dorantes-Alvárez LM.

Clin Ther. 2006 May;28(5):770-82.

PMID:
16861099
6.

[Pharmacological therapy of obesity].

Pagotto U, Vanuzzo D, Vicennati V, Pasquali R.

G Ital Cardiol (Rome). 2008 Apr;9(4 Suppl 1):83S-93S. Italian.

PMID:
18773755
7.

Health-related quality of life in obese outpatients losing weight with very-low-energy diet and behaviour modification: a 2-y follow-up study.

Kaukua J, Pekkarinen T, Sane T, Mustajoki P.

Int J Obes Relat Metab Disord. 2003 Sep;27(9):1072-80.

PMID:
12917713
8.

Efficacy and safety of sibutramine in obese white and African American patients with hypertension: a 1-year, double-blind, placebo-controlled, multicenter trial.

McMahon FG, Fujioka K, Singh BN, Mendel CM, Rowe E, Rolston K, Johnson F, Mooradian AD.

Arch Intern Med. 2000 Jul 24;160(14):2185-91.

PMID:
10904462
9.

Health-related quality of life in obese outpatients losing weight with very-low-energy diet and behaviour modification--a 2-y follow-up study.

Kaukua J, Pekkarinen T, Sane T, Mustajoki P.

Int J Obes Relat Metab Disord. 2003 Oct;27(10):1233-41.

PMID:
14513072
10.

Efficacy and safety of sibutramine for weight loss in obese patients with hypertension well controlled by beta-adrenergic blocking agents: a placebo-controlled, double-blind, randomised trial.

Sramek JJ, Leibowitz MT, Weinstein SP, Rowe ED, Mendel CM, Levy B, McMahon FG, Mullican WS, Toth PD, Cutler NR.

J Hum Hypertens. 2002 Jan;16(1):13-9.

11.

Effect of sibutramine on weight maintenance after weight loss: a randomised trial. STORM Study Group. Sibutramine Trial of Obesity Reduction and Maintenance.

James WP, Astrup A, Finer N, Hilsted J, Kopelman P, Rössner S, Saris WH, Van Gaal LF.

Lancet. 2000 Dec 23-30;356(9248):2119-25.

PMID:
11191537
12.

Second phase of a double-blind study clinical trial on Sibutramine for the treatment of patients suffering essential obesity: 6 months after treatment cross-over.

Fanghänel G, Cortinas L, Sánchez-Reyes L, Berber A.

Int J Obes Relat Metab Disord. 2001 May;25(5):741-7.

PMID:
11360159
13.

Sibutramine is safe and effective for weight loss in obese patients whose hypertension is well controlled with angiotensin-converting enzyme inhibitors.

McMahon FG, Weinstein SP, Rowe E, Ernst KR, Johnson F, Fujioka K; Sibutramine in Hypertensives Clinical Study Group.

J Hum Hypertens. 2002 Jan;16(1):5-11.

14.

Role of sibutramine in the treatment of obese Type 2 diabetic patients receiving sulphonylurea therapy.

Serrano-Rios M, Melchionda N, Moreno-Carretero E; Spanish Investigators.

Diabet Med. 2002 Feb;19(2):119-24.

PMID:
11874427
15.
16.

Effects of sibutramine in obese female subjects with type 2 diabetes and poor blood glucose control.

Gokcel A, Karakose H, Ertorer EM, Tanaci N, Tutuncu NB, Guvener N.

Diabetes Care. 2001 Nov;24(11):1957-60.

PMID:
11679464
17.

Comparison of metabolic effects of orlistat and sibutramine treatment in Type 2 diabetic obese patients.

Derosa G, Cicero AF, Murdolo G, Ciccarelli L, Fogari R.

Diabetes Nutr Metab. 2004 Aug;17(4):222-9.

PMID:
15575343
18.

Effects of sibutramine in overweight, poorly controlled Chinese female type 2 diabetic patients: a randomised, double-blind, placebo-controlled study.

Wang TF, Pei D, Li JC, Tsai WC, Tsai CC, Yao CY, Chang ET, Hsieh MC, Su KY, Kuo SW.

Int J Clin Pract. 2005 Jul;59(7):746-50.

PMID:
15963197
19.

Weight loss and quality of life improvement in obese subjects treated with sibutramine: a double-blind randomized multicenter study.

Di Francesco V, Sacco T, Zamboni M, Bissoli L, Zoico E, Mazzali G, Minniti A, Salanitri T, Cancelli F, Bosello O.

Ann Nutr Metab. 2007;51(1):75-81. Epub 2007 Mar 15.

PMID:
17356258
20.

Predictors of weight loss and maintenance during 2 years of treatment by sibutramine in obesity. Results from the European multi-centre STORM trial. Sibutramine Trial of Obesity Reduction and Maintenance.

Hansen D, Astrup A, Toubro S, Finer N, Kopelman P, Hilsted J, Rössner S, Saris W, Van Gaal L, James W, Goulder M; STORM Study Group.

Int J Obes Relat Metab Disord. 2001 Apr;25(4):496-501.

PMID:
11319653
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk